Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2017 (2017), Article ID 5792925, 7 pages
https://doi.org/10.1155/2017/5792925
Review Article

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis

1College of Health Sciences, Mizan-Tepi University, Mizan Teferi, Ethiopia
2Institute of Health Sciences, Jimma University, Jimma, Ethiopia

Correspondence should be addressed to Tegene Legese Dadi

Received 21 January 2017; Revised 30 March 2017; Accepted 10 April 2017; Published 30 May 2017

Academic Editor: Glenda Gray

Copyright © 2017 Tegene Legese Dadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. B. Bhatti, M. Usman, and V. Kandi, “Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy,” Cureus, vol. 8, no. 3, 2016. View at Publisher · View at Google Scholar
  2. AIDS. Gov., “A time line of HIV/AIDS, 2016,” https://www.aids.gov/hiv-aids-basics/hiv-aids-101/aids-timeline/.
  3. The Henry J. Kaiser Family foundation, “The global HIV/AIDS epidemic, 2016,” http://www.kff.org/global-health-policy/fact-sheet/the-global-hivaids-epidemic/.
  4. WHO, “Global update on the treatment sector response to HIV,” 2014, http://www.who.int/hiv/pub/progressreports/update2014/en/.
  5. UNAIDS, “Global AIDS update,” 2016, http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.
  6. D. R. Kuritzkes, “A fossil record of zidovudine resistance in transmitted isolates of HIV-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13485–13487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. WHO, “Guideline on when to start Antiretroviral Therapy and on pre-exposure prophylaxis for HIV,” 2015, http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf.
  8. World Health Organization, “Unicef, Unaids,” in Global update on HIV treatment: Results, Impact and Opportunities. Global update on HIV treatment: results, impact and opportunities, Geneva, Swizerland, 2013.
  9. A. Spaulding, G. W. Rutherford, and N. Siegfried, “Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral naive individuals,” Cochrane Database of Systematic Reviews, no. 10, Article ID CD008740, 2010. View at Publisher · View at Google Scholar
  10. B. P. Clayden, S. Collins, M. Frick et al., “Heptitis C Virus (HCV), and Tuberculosis (TB). Drugs, diagnosis, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in Development,” 2015.
  11. K. Scarsi, K. Darin, H. Rawizza et al., “TDF-3TC-NVP is inferior to ZDV-3TC-NVP in a large ART program in Nigeria,” Journal of Acquired Immune Deficiency Syndrome, pp. 517–521, 2010. View at Google Scholar
  12. A. A. Babafemi, “Comparison of clinical and immunological responses to zidovudine (ZDV) and tenofovir (TDF) containing ARV regimens in patients taking HAART at Roma health service area of Lesetho,” Journal of Acquired Immune Deficiency Syndrome, vol. 45, no. 7, pp. 8–11, 2010. View at Google Scholar
  13. C. L. N. Woodward, A. M. Hall, I. G. Williams et al., “Tenofovir-associated renal and bone toxicity,” HIV Medicine, vol. 10, no. 8, pp. 482–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Omeje and C. I. Okwundu, “Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV,” Cochrane Database of Systematic Reviews, no. 5, Article ID CD007276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. B. Campbell, L. M. Smeaton, N. Kumarasamy et al., “Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings,” PLoS Medicine, vol. 9, no. 8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. H. Chi, A. Mwango, M. Giganti et al., “Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 1, pp. 63–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Pozniak, J. E. Gallant, E. DeJesus et al., “Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - A 96-week analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 5, pp. 535–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. E. Gallant, A. L. Pozniak, E. Dejesus et al., “Tenofovir disoproxil fumarate, emtricitabine, and efavirenz Versus fixed-dose zidovudine/lamivudine and efavirenzt in antiretroviral-naive patients virologic, immunologic, and morphologic changes—a 144-weeks analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 5, pp. 535–540, 2006. View at Google Scholar · View at Scopus
  19. J. R. Arribas, A. L. Pozniak, J. E. Gallant et al., “Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - A 96-week analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 5, pp. 535–540, 2006. View at Google Scholar · View at Scopus
  20. R. Sánchez-de la Rosa, L. Herrera, and S. Moreno, “Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients,” Clinical Therapeutics, vol. 30, no. 2, pp. 372–381, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. L. C. Fernández Lisón, E. Pujol De La Llave, A. Hevia Alonso, M. T. Garrido Martínez, and C. Bocanegra Martín, “Cost-effectiveness analysis of tenofovir versus zidovudine in combination therapy with efavirenz and lamivudine for the treatment of HIV in naive patients,” Farmacia Hospitalaria, vol. 29, no. 1, pp. 11–17, 2005. View at Publisher · View at Google Scholar · View at Scopus